

Special Issue

Navigating the Evolving Landscape of Gynecology: From Diagnosis to Treatment

Message from the Guest Editors

The landscape of gynecological oncology has been transformed by advancements in precision medicine and immunotherapy, ushering in a new era of personalized cancer care. From targeted molecular therapies to novel immunomodulatory agents, these groundbreaking treatments hold promise for improved outcomes and enhanced quality of life for women with gynecological malignancies.

In this update on gynecology, we embark on a comprehensive journey from diagnosis to treatment, exploring the latest advancements that shape the landscape of women's health care. By delving into the intricate interplay between cutting-edge diagnostics and innovative therapeutic modalities, we aim to provide insights into the evolving landscape of gynecological care and its profound impact on patient outcomes and well-being. Therefore, original articles, reviews, and meta-analyses are welcome in this Special Issue.

Guest Editors

Dr. Ferdinando Antonio Gulino


Unit of Gynecology and Obstetrics, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University Hospital "G. Martino", 98124 Messina, Italy

Dr. Stefano Cianci

Department of Human Pathology of Adult and Childhood "G. Barresi" Unit of Gynecology and Obstetrics, University of Messina, 98125 Messina, Italy

Deadline for manuscript submissions

closed (15 July 2025)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/199542

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).